Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
JAMA Network Open · 07.07.2025 · 8 (7) · e2519236
DOI: 10.1001/jamanetworkopen.2025.19236 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 07.07.2025. Verfasst von Charlotte Le Cornet und 56 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Contraceptives, Oral, Estrogen Replacement Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization, NCI NIH HHS, Cancer Research UK.
Abstract (Originalsprache)
Importance Etiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.
Objective
To examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes. Design, Setting, and Participants This study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024. Exposure MHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use). Main Outcomes and Measures Breast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-<25; overweight, 25-<30; or obesity, ≥30).
Results
This study included 42 269 individuals with breast cancer (11 901 [28.2%] premenopausal and 30 368 [71.8%] postmenopausal; 23 353 [55.2%] had a known intrinsic-like subtype) and 71 072 control participants. The mean (SD) age of all participants was 57.9 (10.9) years. In postmenopausal women, associations between current MHT use (EPT or ET) and breast cancer differed by subtype. Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]). EPT use increased the odds of being diagnosed with luminal B–like tumors solely in women with healthy weight (OR, 1.47 [95% CI, 1.17-1.86]). Current ET use was positively associated with luminal A–like disease in women with healthy weight only (OR, 1.16 [95% CI, 1.01-1.32]), showing inverse associations with higher BMI (obesity: OR, 0.65 [95% CI, 0.50-0.85]). In premenopausal women, recent OC use was associated with luminal B–ERBB2-like (OR, 1.50 [95% CI, 1.09-2.08]), ERBB2 enriched–like (OR, 2.33 [95% CI, 1.55-3.51]), and triple-negative (OR, 1.75 [95% CI, 1.33-2.29]; P < .04 for heterogeneity) tumors. Conclusions and Relevance In this study, clear differences were observed in associations between current EPT use and luminal-like breast cancer subtypes and other subtypes. EPT users with healthy weight were more likely to be diagnosed with luminal-like breast cancer compared with nonusers. Subtype heterogeneity was less apparent in associations of OC and ET use. Future studies on contemporary formulations, patterns of use, and routes of administration of exogenous hormone usage are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
- Division of General Internal Medicine, Department of Medicine, University of California, San Francisco.
- Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Institut National de la Santé et de la Recherche Médicale, Gustave Roussy, Centre for Epidemiology and Population Health, Villejuif, France.
- Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
Förderung
- World Health Organization
- NCI NIH HHS
- Cancer Research UK
- CIHR
Zitieren
APA
Le Cornet, C., Jung, A. Y., Behrens, S., Middha, P., Truong, T., Jernström, H., Bolla, M. K., Wang, Q., Southey, M. C., Beane Freeman, L. E., Koutros, S., Stone, J., Rennert, G., Shulman, K., Aronson, K. J., Murphy, R. A., Guénel, P., Patel, A. V., Bodelon, C., …, & Chang-Claude, J. (2025). Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer. JAMA Network Open, 8(7), e2519236. https://doi.org/10.1001/jamanetworkopen.2025.19236
Vancouver
Le Cornet C, Jung AY, Behrens S, Middha P, Truong T, Jernström H, et al. Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer. JAMA Network Open. 2025;8(7):e2519236. doi:10.1001/jamanetworkopen.2025.19236
BibTeX
@article{LeCornet2025,
author = {Le Cornet, Charlotte and Jung, Audrey Y and Behrens, Sabine and Middha, Pooja and Truong, Thérèse and Jernström, Helena and Bolla, Manjeet K and Wang, Qin and Southey, Melissa C and Beane Freeman, Laura E and Koutros, Stella and Stone, Jennifer and Rennert, Gad and Shulman, Katerina and Aronson, Kristan J and Murphy, Rachel A and Guénel, Pascal and Patel, Alpa V and Bodelon, Clara and Teras, Lauren R and Shahi, Shamim and Lacey, James V and Dossus, Laure and Kaaks, Rudolf and Holleczek, Bernd and Brenner, Hermann and Brauch, Hiltrud and Hoppe, Reiner and Czene, Kamila and Hall, Per Frans Leonard and Mannermaa, Arto and Wu, Anna H and Obi, Nadia and Michailidou, Kyriaki and Panayiotidis, Mihalis I and McLean, Catriona and Haiman, Christopher A and Augustinsson, Annelie and Zheng, Wei and Shu, Xiao-Ou and Perou, Charles M and Troester, Melissa A and Van Alsten, Sarah and Eliassen, A Heather and Abubakar, Mustapha and Kraft, Peter and Ahearn, Thomas U and Evans, D Gareth and Wolk, Alicja and Milne, Roger L and Easton, Douglas F and Pharoah, Paul D P and Schmidt, Marjanka K and García-Closas, Montserrat and Vachon, Celine M and Fortner, Renée T and Chang-Claude, Jenny},
title = {Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {7},
pages = {e2519236},
doi = {10.1001/jamanetworkopen.2025.19236}
}
EUVIMED